CS10 (Cagrilintide 5 mg + Semaglutide 5 mg)

CS10 is a combined research vial uniting two complementary peptides: cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 analogue, at 5 mg each. The rationale of the combination is that the two molecules act on distinct satiety pathways — amylin through the brainstem, GLP-1 through incretin receptors — which the literature reports as mutually reinforcing. The combined format lets laboratories study the concurrent action of the two pathways within a single experimental protocol, from food-intake and body-weight models to receptor-signalling assays. Each component contributes its own profile: cagrilintide the amylinergic signalling, semaglutide the incretin axis. For laboratory research use only. Not for human or veterinary use.